Organogenesis Holdings Inc. (ORGO)

Organogenesis Holdings Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	5.82	4.95	15.53	94.2	17.23	-39.28
Depreciation & Amortization	23.76	23.45	18.03	16.68	8.18	9.83
Share-Based Compensation	9.49	9	6.55	3.86	1.66	0.94
Other Operating Activities	-13.23	-6.47	-15.26	-52.76	-21.61	-5.58
Operating Cash Flow	25.83	30.92	24.86	61.98	5.47	-33.53
Operating Cash Flow Growth	40.61%	24.37%	-59.89%	1033.88%	-	-
Capital Expenditures	-19.02	-24.36	-33.9	-31.22	-17.68	-6.23
Acquisitions	0	0	0	0	-5.82	0
Investing Cash Flow	-19.02	-24.36	-33.9	-31.22	-23.5	-6.23
Share Issuance / Repurchase	0.18	0	2.07	2.2	61.9	41.5
Debt Issued / Paid	-5.9	-5.17	-3.01	-2.01	-15.91	37.23
Other Financing Activities	-1.15	-0.33	-1.26	-1.22	-3.52	-
Financing Cash Flow	-6.88	-5.51	-2.2	-1.04	42.47	78.73
Net Cash Flow	-0.07	1.05	-11.24	29.72	24.44	38.97
Free Cash Flow	6.81	6.55	-9.04	30.76	-12.21	-39.76
Free Cash Flow Margin	1.56%	1.51%	-2.00%	6.58%	-3.61%	-15.24%
Free Cash Flow Per Share	0.05	0.05	-0.07	0.24	-0.11	-0.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).